Assessment of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients

Abstract

Purpose: Chemotherapy-induced febrile neutropenia (CIFN) is an adverse drug reaction which needs medical attention. The treatment options for the CIFN are mandatory to improve treatment outcomes and quality of life. Methods: A prospective observational study was conducted in the in-patients and out-patients of oncology department who received chemotherapy from October 2016 to March 2017. The information such as demographics (age, gender, and comorbidities), complaints on admission, hematological investigations (neutrophil counts, platelet counts, hemoglobin levels, erythrocyte sedimentation rate, and white blood cells), type of tumor, stage of cancer, prophylaxis, cycle of antineoplastic chemotherapy that cause febrile neutropenia, treatment history, and outcome data were obtained from the patient's clinical record. The Multinational Association for Supportive Care in Cancer score and Absolute Neutrophil Count grading was used to predict the patient's risk of developing CIFN. Results: Out of 200 patients, 19 patients developed 22 episodes of CIFN. The overall occurrence of CIFN during the study was 9.5%. The higher incidence of CIFN has been observed among male gender (57.89%), stage III patients (42.10%), solid tumor (73.68%), and double chemotherapy regimen (59.1%). The higher incidence of CIFN was developed in I cycle (36.36%) followed by II cycle (22.72%) and VI cycle (18.18%). Conclusions: The incidence of CIFN during the study was 9.5%. In the 19 chemotherapy-induced FN patients, there has no significant effect of prophylaxis to prevent the febrile neutropenia.

Keywords

Adverse drug reactions - cancer - chemotherapy - febrile neutropenia - incidence

Publication History

Article published online:
03 June 2021

• References

• 1 Rang HP, Ritter JM, Flower RJ, Henderson G. Drugs used for the treatment of infection and cancer. Rang and Dale's Pharmacology. Anticancer Drugs. 8th ed. London: Elsevier Churchill Livingstone; 2012: 676-90
• 2 Morin PJ, Trent JM, Collins FS, Vogenstein B. Cancer Genetics. In: Kasper DC, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. editors Harrison's Principles of Internal Medicine. Part 10. 19th ed. 3. Sec. 3. Ch. 101e United States of America: McGraw-Hill Education; 2016: 1-10
• 3 Rosa RG, Goldani LZ. Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother 2014; 58: 3799-803
• 4 Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. et al. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs 2015; 26: 1054-60
• 5 Garnica M, Nouér SA, Pellegrino FL, Moreira BM, Maiolino A, Nucci M. et al. Ciprofloxacin prophylaxis in high risk neutropenic patients: Effects on outcomes, antimicrobial therapy and resistance. BMC Infect Dis 2013; 13: 356
• 6 Yu MG, Villalobos RE, Juan-Bartolome MJ, Berba RP. Predictors of outcome and severity in adult Filipino patients with febrile neutropenia. Adv Hematol 2015; 2015: 920838
• 7 Bengre ML, Venkatraya PM, Arun S, Prasad K, Gopalkrishna BK. Evaluation of the multinational association for supportive care in cancer (MASCC) score for identifying low risk febrile neutropaenic patients at a South Indian tertiary care centre. J Clin Diagnostic Res 2012; 6: 839-43
• 8 Aapro M, Ludwig H, Bokemeyer C, Gascón P, Boccadoro M, Denhaerynck K. et al. Predictive modeling of the outcomes of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar filgrastim (MONITOR-GCSF study). Ann Oncol 2016; 27: 2039-45
• 9 Ahn S, Lee YS, Chun YH, Kwon IH, Kim W, Lim KS. et al. Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia. Support Care Cancer 2011; 19: 1151-8
• 10 Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA. et al. Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239-45
• 11 Mateti UV, Nekkanti H, Vilakkathala R, Rajakannan T, Mallayasamy S, Ramachandran P. et al. Pattern of angiotensin-converting enzyme inhibitors induced adverse drug reactions in South Indian teaching hospital. N Am J Med Sci 2012; 4: 185-9
• 12 Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. Am J Hosp Pharm 1992; 49: 2229-32
• 13 Gholami K, Shalviri G. Factors associated with preventability, predictability, and severity of adverse drug reactions. Ann Pharmacother 1999; 33: 236-40
• 14 Catic T, Mekic-Abazovic A, Sulejmanovic S. Cost of febrile neutropenia treatment in bosnia and herzegovina. Mater Sociomed 2016; 28: 112-5
• 15 Sammut SJ, Mazhar D. Management of febrile neutropenia in an acute oncology service. QJM 2012; 105: 327-36
• 16 Weycker D, Li X, Edelsberg J, Barron R, Kartashov A, Xu H. et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract 2015; 11: 47-54
• 17 Culakova E, Poniewierski MS, Wolff DA, Dale DC, Crawford J, Lyman GH. et al. The impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: A prospective cohort study. Springerplus 2015; 4: 396
• 18 Shiota M, Yokomizo A, Takeuchi A, Kiyoshima K, Inokuchi J, Tatsugami K. et al. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer. Support Care Cancer 2014; 22: 3219-26
• 19 Talwar V, Nirni SS, Mallavarapu KM, Ramkumar A, Sinha N. Safety and tolerability of peg-grafeel™, a pegfilgrastim, for the prophylactic treatment of chemotherapy-induced neutropenia and febrile neutropenia: A prospective, observational, postmarketing surveillance study in India. South Asian J Cancer 2017; 6: 20-4